Table 3.
Clinical course among cancer patients with SARS-CoV-2 infection.
| n (%) | Overall respiratory failure |
ARDS |
||||
|---|---|---|---|---|---|---|
| N = 34 | p value | N = 24 | p value | |||
| Primary tumour site | ||||||
| Lung | 9 (26%) | 0.54 | 7 (29%) | 0.54 | ||
| Other site | 25 (74%) | 17 (71%) | ||||
| Metastatic status | ||||||
| Non-metastatic | 5 (14%) | 0.53 | 3 (13%) | 0.∙5 | ||
| Metastatic | 29 (86%) | 21 (87%) | ||||
| Tumour pulmonary involvement | 0.11 | |||||
| Yes | 14 (41%) | 0.18 | 11 (46%) | 0.11 | ||
| No | 20 (59% | 13 (54%) | ||||
| Cancer treatment | ||||||
| Chemotherapy | 19 (56%) | 0.∙28 | 7 (29%) | 0.64 | ||
| Endocrine | 6 (18%) | 4 (17%) | ||||
| Target therapy | 2 (6%) | 1 (4%) | ||||
| Inmunotherapy | 4 (12%) | 3 (13%) | ||||
| Radiological pattern | ||||||
| Unilobar/bilobar | 7 (20%) | <0.001 | 2 (8%) | <0.001 | ||
| Bilateral/multilobar | 27 (79%) | 22 (91%) | ||||
| Age | ||||||
| <50 | 3 (9%) | 2 (8%) | ||||
| 50–70 | 19 (56%) | 12 (50%) | ||||
| >70 | 12 (35%) | 0.8 | 10 (42%) | 0.5 | ||
| Smoking history | ||||||
| Never smoker | 15 (44%) | 0.77 | 0.32 | 11 (46%) | 0.92 | 0.41 |
| Former smoker | 14 (42%) | 9 (37%) | ||||
| Current smoker | 5 (14%) | 4 (17%) | ||||
| Sex | ||||||
| Male | 19 (56%) | 0.74 | 13 (54%) | 0.92 | ||
| Female | 15 (44%) | 11 (46%) | ||||
| Comorbidities | ||||||
| Previous anaemia | 9 (27%) | 0.01 | 6 (25%) | 0.12 | ||
| HTA | 20 (59%) | 0.44 | 14 (58%) | 0.65 | ||
| Diabetes | 6 (18%) | 0.36 | 6 (25%) | 0.16 | ||
| Chronic kidney disease | 4 (12%) | 0.22 | 3 (13%) | 0.29 | ||
| Cardiopathy | 6 (18%) | 0.76 | 2 (8%) | 0.1 | ||
| COPD | 8 (24%) | 0.78 | 5 (20%) | 0.83 | ||
| Previous VTED | 7 (21%) | 0.9 | 6 (25%) | 0.5 | ||
| Previous ACEi/ARBs | 5 (14%) | 0.6 | 3 (13%) | 0.97 | ||
| Anticoagulant therapy | 8 (24%) | 0.53 | 6 (25%) | 0.5 | ||
| Chronic corticosteroids | ||||||
| <10 mg | 2 (6%) | 0.∙32 | 1 (4%) | 0.77 | ||
| >10 mg | 8 (24%) | 5 (20%) | ||||
Numbers are expressed as n/N for each category. p values for Fisher's exact test.
VTE, venous thromboembolic disease; COPD, chronic obstructive pulmonary disease, ACEi/ARBs, angiotensin converting enzyme inhibitor/angiotensin receptor blockers; HTA, hypertension.